Zydus	
dedicated/ife	2

## Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015. Tel. No. (+91-79) 686 8100 Fax No. : (+91-79) 686 2365/66 Website : www.zyduscadila.com

CONSOLIDATED			Sr. No	0.	Particulars		COMPANY	
	upees in Millions						upees in Million	
For the Quart		Previous				For the Quar		Pr
June 3	0,	Accounting				June	30,	Acco
		year ended on						year end
2007	2006	March 31,				2007	2006	Mar
2007	2000	2007				2007	2000	
		[ Audited ]						[ Au
			1		Sales & Income from operations :			
5855	4565	18747		А	Gross Sales	4645	3775	1
246	204	892		В	Less : Excise Duty	216	203	
5609	4361	17855		С	Net Sales	4429	3572	1
113	97	433		D	Other Income from Operations	94	77	
5722	4458	18288		Е	Total sales and other income from operations	4523	3649	1
3	0	1	2		Other Income	106	105	
5725	4458	18289	3		Total Income	4629	3754	1
			4		Expenditure :			
68	(322)	(917)		А	Increase / Decrease [ - ] in Stock in Trade	87	(231)	
2026	1844	7289		B	Consumption of Materials	1637	1521	
579	477	2110		С	Staff Cost	454	393	
1937	1561	6285		D	Other Expenditure	1560	1288	
4610	3560	14767		Е	Total Expenditure	3738	2971	1
1115	898	3522	5		Profit before Interest, Depreciation & Tax	891	783	
73	56	234	6	А	Interest & Financial Charges	52	49	
(91)	13	(11)		В	Exchange Rate Fluctuations on Foreign Currency Loans	(91)	13	
(18)	69	223		С	Total Financial cost	(39)	62	
1133	829	3299	7		Profit before Depreciation & Tax	930	721	
239	197	823	8		Depreciation & Amortisation	176	159	
894	632	2476	9		Profit before Tax & Exceptional Items	754	562	
0	49	263	10		Add : Exceptional Items	0	0	
894	681	2739	11		Profit before tax	754	562	
			12		Provision for Taxation :			
101	57	244		A	Current Tax	70	51	
5	12	37		В	Deferred Tax	5	12	
15	7	43		С	Fringe Benefit Tax	15	7	
121	76	324		Е	Total provision for taxation	90	70	
773	605	2415	13		Profit after tax	664	492	
(34)	(21)	(77)	14		Adjustments on consolidation	0	0	
739	584	2338	15		Net Profit	664	492	
628	314	628	16		Paid up Equity Share Capital [ Face Value Rs. 5 /- ]	628	314	
			17		Reserves excluding Revaluation Reserve			
5.89	4.65	18.62	18		E P S [ Rs. ] [ For the period - not Annualised ]:	5.29	3.92	
	1.00	10:02	19		Aggregate of Non-promoter Shareholding :	0.27	0.72	
			17			35150458	17575229	351
					- Number of Equity Shares			
					- Percentage of Shareholding	27.98%	27.98%	2
Notes :								
[1]	The above results w	ere reviewed by the Audi	t Committ	tee a	nd then approved by the Board of Directors at their meeting held of	on July 31, 2007 and		
				t a lii	nited review of the financial results of the Company for the quarter	ended June 30, 2007		
[2]	During the quarter,	the Company has acquire	d:					
	[ A ] 100% stake in	Quimica e Farmaceutica	Nikkho do	Braz	til Ltda. [ Nikkho ], through its wholly owned Brazilian Subsidiary.			
	[B] additional 50%	shares in Sarabhai Zydu	s Animal H	Healt	h Limited at Rs. 686 Millions, due to which it became wholly owned	subsidiary of the Corr	ipany.	
[3]	During the quarter,	the Company has investe	d :					
	[ A ] Liva Healthcare				Rs. 482 Millions.			
	[ B ] Zydus Internati				Rs. 136 Millions.			
	[ C ] Zydus BSV Pha				Rs. 8 Millions.			
	[ D ] M/s. Zydus Hea				Rs. 118 Millions.			
			with TC!	Ento		on Juno 19		
			with IGL	CITE	rprise LLC, USA and has incorporated " Zydus Noveltech Inc. USA "	UI JUIR 10,		
	-	ake of the Company.						
	The status of investo							
					disposed off during the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the end of the quarter - 24, - pending at the quarter	uarter - Nil.		
[6]	The Company has or	ne segment of activity viz	. " Pharm	naceu	ticals ".			
							der of the Board,	
						For Cadila He	ealthcare Limited,	
							Pankaj R. Patel	
	007					Chairman & M	Anaging Director	
abad, 31st July, 2								